Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...
Now, phase 3 results with a new drug from Sobi and Selecta suggests there could be another treatment option in the offing. Armed with a pair of phase 3 trial readouts, the two companies are ...
As of 2:32:52 PM GMT+1. Market Open. Loading Chart for SOBI.ST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback